I have to chime in with tc. It’sjust too expensive and time consuming to complete the reformulation and do the trials necessary for bringing O-L to market. That doesn’t even include navigating all the red tape the FDA would lay down.

I do not see R&D as essential to the NuGenerex business model. AE37, O-L, and some of the newer acquisitions are more likely to be sold off or spun off if there are no synergies with plans for the MSO. There is much to be done and unknown developments could change my opinion, but under present circumstances, that’s how I think it will play out. No matter how any of us feel about O-L, sounds like a good question for the GG.